On March 1, 2021, Formycon announced that it plans to resubmit its BLA for its Lucentis® Biosimilar Candidate FBY201 (ranibizumab) in the first half of 2021.  Formycon expects to submit its application to the EMA soon thereafter, and will also seek approval in Canada, Australia, the United Kingdom and Switzerland.

Also on March 1, 2021, Biocon Biologics, Ltd. announced that the EMA CHMP has recommended approval of Biocon’s biosimilar bevacizumab, which will be marketed as Abevmy.  Biocon co-developed its product with Viatris.  Biocon expects final approval of its product in May 2021.